<DOC>
	<DOC>NCT00536835</DOC>
	<brief_summary>This is a first time in human study that is being done to determine the maximum tolerated dose and initial pharmacokinetic parameters of GSK461364, given by IV, in adult subjects with solid tumors and Non-Hodgkins lymphoma.</brief_summary>
	<brief_title>Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Confirmed diagnosis of advanced solid tumor or NonHodgkins Lymphoma (excluding HIVassociated lymphoma) that has relapsed or is refractory to standard therapies At least 18 years of age Female who are of nonchildbearing potential or who have a negative pregnancy test who uses approved contraception Male with a female partner of childbearing potential must have had a vasectomy or both are using approved contraception Lab values that are within range as described in the protocol Paraffinembedded archival tumor tissue available for testing Signed written informed consent Undergone major surgery or received anticancer therapy History of hemolytic anemia Clinical lab tests that are out of range as described in the protocol Females who are pregnant or lactating Significant heart problems Serious or unstable preexisting medical or psychiatric condition Are not able to comply with the study protocol Use of prohibited medications Have low blood pressure Evidence of symptomatic or untreated central nervous system involvement and require corticosteroids or antiepileptic meds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>First time in human</keyword>
	<keyword>PLK1 inhibitor</keyword>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>GSK461364</keyword>
</DOC>